Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jtm/taaf003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Toxic travels: the rising threat of methanol poisoning in international travellers.
J Travel Med
January 2025
School of Medicine, College of Medicine, Nursing and Health Sciences, University of Galway, Galway, Ireland.
Article Synopsis
- FT596 is a novel cancer therapy using iPSC-derived CAR NK cells targeting CD19, designed to assess its safe dosage and effectiveness alone and with rituximab in patients with B-cell lymphoma.
- This phase 1 trial involved patients with relapsed or refractory B-cell lymphoma, administering FT596 after chemotherapy, with separate regimens for those receiving rituximab and those who did not.
- The study measured potential side effects while determining the optimal dose of FT596 and allowed modifications to the treatment based on patient tolerance and response.
Dolomite dissolution, pH neutralization, and potentially toxic element immobilization in stormwater bioretention beds.
Sci Total Environ
January 2025
Temple University, Department of Civil and Environmental Engineering, 1947 North 12(th) Street, Philadelphia, PA 19122, United States. Electronic address:
The importance of pH in stormwater bioretention beds cannot be overstated since it impacts plant and microbial populations and removal of potentially toxic elements (PTEs) from stormwater runoff. This study investigated the effects of dolomite amendment on pH neutralization and subsequent PTE immobilization in bioretention media. To assess dolomite dissolution, pH neutralization, and PTE immobilization, engineered bioretention media was amended with different dolomite ratios and samples of dolomite-amended media were collected from two bioretention beds, one and two months after installation.
View Article and Find Full Text PDFOutcomes in patients with acute myeloid leukemia older than 70 years within the last 30 years, a single center experience.
Ann Hematol
January 2025
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Moorenstr. 5, Duesseldorf, 40225, Germany.
As median age of patients with acute myeloid leukemia is 72 years, older patients continue to be a vulnerable cohort representing significant challenges in clinical practice. Patient-specific comorbidities as well as leukemia-specific unfavorable molecular- and cytogenetics confer even poorer outcomes. Treatment of AML therefore needs to be less toxic to prevent harm while lowering or eradicating leukemic burden to prolong survival.
View Article and Find Full Text PDFA first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies.
Eur J Cancer
November 2024
David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Purpose: MAK683, a first-in-class and highly selective allosteric inhibitor of the embryonic ectoderm development subunit of polycomb repressive complex 2, has shown sustained antitumor activity in tumor xenograft models. This first-in-human phase 1/2 study evaluated the safety, pharmacokinetics (PK), and clinical activity of single-agent MAK683 in advanced malignancies.
Methods: MAK683 was administered fasted once daily or twice daily continuously in 28-day treatment cycles.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!